Takeda Pharmaceutical (TAK) EBT Margin Growth (1y) (2018 - 2026)
Powered by 
Analysis
Takeda Pharmaceutical (TAK) EBT Margin Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -68.00 |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 1,510.00 |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -3,574.00 |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -261.00 |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -2,512.00 |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -504.00 |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | -101.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | -356.00 |
| 10 | Takeda Pharmaceutical | 2.61 Bn | -3.19 Bn | 5.10 Bn | -27.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27.00 |
| Mar 31, 2026 | 87.00 |
| Dec 31, 2025 | -3,139.00 |
| Sep 30, 2025 | 86.00 |
| Jun 30, 2025 | 230.00 |
| Mar 31, 2025 | 116.00 |
| Dec 31, 2024 | -1,474.00 |
| Sep 30, 2024 | -218.00 |
| Jun 30, 2024 | -145.00 |
| Mar 31, 2024 | -338.00 |
| Dec 31, 2023 | -521.00 |
| Sep 30, 2023 | 374.00 |
| Jun 30, 2023 | -323.00 |
| Mar 31, 2023 | -824.00 |
| Dec 31, 2022 | 176.00 |
| Sep 30, 2022 | -83.00 |
| Jun 30, 2022 | -749.00 |
| Mar 31, 2022 | -602.00 |
| Dec 31, 2021 | -511.00 |
| Sep 30, 2021 | 787.00 |